The diabetogenic action of statins - mechanisms and clinical implications (Q38669513)

5 September 2017

title

The diabetogenic action of statins - mechanisms and clinical implications (English)

1 reference

5 September 2017

D John Betteridge

1 reference

5 September 2017

Rafael Carmena

series ordinal

1 reference

5 September 2017

publication date

15 December 2015

1 reference

Nature Reviews Endocrinology

5 September 2017

published in

1 reference

5 September 2017

1 reference

5 September 2017

1 reference

5 September 2017

page(s)

99-110

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2015.194

5 September 2017

1 reference

The SREBP pathway: regulation of cholesterol metabolism by proteolysis of a membrane-bound transcription factor

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2015.194

Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2015.194

Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2015.194

The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2015.194

The safety of statins in clinical practice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2015.194

Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2015.194

Pravastatin and the development of diabetes mellitus: evidence for a protective treatment effect in the West of Scotland Coronary Prevention Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2015.194

Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2015.194

Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2015.194

Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2015.194

Cardiovascular event reduction versus new-onset diabetes during atorvastatin therapy: effect of baseline risk factors for diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2015.194

Statin therapy and risk of developing type 2 diabetes: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2015.194

Higher potency statins and the risk of new diabetes: multicentre, observational study of administrative databases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2015.194

Statins for the primary prevention of cardiovascular events in women with elevated high-sensitivity C-reactive protein or dyslipidemia: results from the Justification for the Use of Statins in Prevention: An Intervention Trial Evaluating Rosuvastati

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2015.194

Dyslipidaemia in the metabolic syndrome and type 2 diabetes: pathogenesis, priorities, pharmacotherapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2015.194

Statin use and risk of diabetes mellitus in postmenopausal women in the Women's Health Initiative.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2015.194

Statin therapy and related risk of new-onset type 2 diabetes mellitus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2015.194

The use of statins in people at risk of developing diabetes mellitus: evidence and guidance for clinical practice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2015.194

Predictors of new-onset diabetes in patients treated with atorvastatin: results from 3 large randomized clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2015.194

Cardiovascular benefits and diabetes risks of statin therapy in primary prevention: an analysis from the JUPITER trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2015.194

Could changes in adiponectin drive the effect of statins on the risk of new-onset diabetes? The case of pitavastatin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2015.194

Pathogenesis and management of the diabetogenic effect of statins: a role for adiponectin and coenzyme Q10?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2015.194

Statins: beneficial or adverse for glucose metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2015.194

Effect of high-dose pitavastatin on glucose homeostasis in patients at elevated risk of new-onset diabetes: insights from the CAPITAIN and PREVAIL-US studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2015.194

Increased risk of diabetes with statin treatment is associated with impaired insulin sensitivity and insulin secretion: a 6 year follow-up study of the METSIM cohort

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2015.194

Influence of pitavastatin on glucose tolerance in patients with type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2015.194

New evidence on pitavastatin: efficacy and safety in clinical studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2015.194

Risk of diabetes in patients treated with HMG-CoA reductase inhibitors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2015.194

Effect of pitavastatin on glucose, HbA1c and incident diabetes: A meta-analysis of randomized controlled clinical trials in individuals without diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2015.194

Statins and glycaemic control in individuals with diabetes: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2015.194

Effect of intensive control of glucose on cardiovascular outcomes and death in patients with diabetes mellitus: a meta-analysis of randomised controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2015.194

Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2015.194

A dysglycaemic effect of statins in diabetes: relevance to clinical practice?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2015.194

Effect of statin therapy on incident type 2 diabetes mellitus in patients with clinically manifest vascular disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2015.194

High-dose statin therapy does not induce insulin resistance in patients with familial hypercholesterolemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2015.194

Association between familial hypercholesterolemia and prevalence of type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2015.194

HMG-coenzyme A reductase inhibition, type 2 diabetes, and bodyweight: evidence from genetic analysis and randomised trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2015.194

Cellular basis of insulin insensitivity in large rat adipocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2015.194

Mechanisms of decreased insulin responsiveness of large adipocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2015.194

Increased adipose angiotensinogen gene expression in human obesity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2015.194

Adipose Expression of Tumor Necrosis Factor-α: Direct Role in Obesity-Linked Insulin Resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2015.194

Cholesterol, a cell size-dependent signal that regulates glucose metabolism and gene expression in adipocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2015.194

Cholesterol depletion disrupts caveolae and insulin receptor signaling for metabolic control via insulin receptor substrate-1, but not for mitogen-activated protein kinase control

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2015.194

Inhibition of isoprenoid biosynthesis causes insulin resistance in 3T3-L1 adipocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2015.194

Effects of atorvastatin and pravastatin on signal transduction related to glucose uptake in 3T3L1 adipocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2015.194

Coenzyme Q10 ameliorates the reduction in GLUT4 transporter expression induced by simvastatin in 3T3-L1 adipocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2015.194

Type 2 diabetes as an inflammatory disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2015.194

Inflammation and insulin resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2015.194

Interleukin-1beta-induced insulin resistance in adipocytes through down-regulation of insulin receptor substrate-1 expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2015.194

Long-term treatment with interleukin-1beta induces insulin resistance in murine and human adipocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2015.194

The NLRP3 inflammasome instigates obesity-induced inflammation and insulin resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2015.194

The inflammasome-mediated caspase-1 activation controls adipocyte differentiation and insulin sensitivity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2015.194

Upregulated NLRP3 inflammasome activation in patients with type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2015.194

Fluvastatin causes NLRP3 inflammasome-mediated adipose insulin resistance.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2015.194

Differing effect of statins on insulin sensitivity in non-diabetics: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2015.194

Adiponectin and adiponectin receptors in insulin resistance, diabetes, and the metabolic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2015.194

Adiponectin levels and risk of type 2 diabetes: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2015.194

Genetic variation in the gene encoding adiponectin is associated with an increased risk of type 2 diabetes in the Japanese population.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2015.194

Association of adiponectin mutation with type 2 diabetes: a candidate gene for the insulin resistance syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2015.194

Association of the T-G polymorphism in adiponectin (exon 2) with obesity and insulin sensitivity: interaction with family history of type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2015.194

Low- and high-density lipoproteins modulate function, apoptosis, and proliferation of primary human and murine pancreatic beta-cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2015.194

HDL and LDL cholesterol significantly influence beta-cell function in type 2 diabetes mellitus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2015.194

Beta-cell ABCA1 influences insulin secretion, glucose homeostasis and response to thiazolidinedione treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2015.194

Effects of high-density lipoproteins on pancreatic beta-cell insulin secretion

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2015.194

An intracellular role for ABCG1-mediated cholesterol transport in the regulated secretory pathway of mouse pancreatic beta cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2015.194

Cholesterol accumulation increases insulin granule size and impairs membrane trafficking

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2015.194

Modulation of insulin secretion from normal rat islets by inhibitors of the post-translational modifications of GTP-binding proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2015.194

Blockade of mevalonate production by lovastatin attenuates bombesin and vasopressin potentiation of nutrient-induced insulin secretion in HIT-T15 cells. Probable involvement of small GTP-binding proteins.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2015.194

Inhibition by simvastatin, but not pravastatin, of glucose-induced cytosolic Ca2+ signalling and insulin secretion due to blockade of L-type Ca2+ channels in rat islet beta-cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2015.194

Atorvastatin helps preserve pancreatic β cell function in obese C57BL/6 J mice and the effect is related to increased pancreas proliferation and amelioration of endoplasmic-reticulum stress

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2015.194

Use of the oral glucose tolerance test to assess insulin release and insulin sensitivity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2015.194

Insulin sensitivity indices obtained from oral glucose tolerance testing: comparison with the euglycemic insulin clamp

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2015.194

Statins and new-onset diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2015.194

The Finnish Diabetes Prevention Study (DPS): Lifestyle intervention and 3-year results on diet and physical activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2015.194

Sustained reduction in the incidence of type 2 diabetes by lifestyle intervention: follow-up of the Finnish Diabetes Prevention Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2015.194

Reduction in the Incidence of Type 2 Diabetes with Lifestyle Intervention or Metformin

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2015.194

The 10-year cost-effectiveness of lifestyle intervention or metformin for diabetes prevention: an intent-to-treat analysis of the DPP/DPPOS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2015.194

Statin use before diabetes diagnosis and risk of microvascular disease: a nationwide nested matched study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2015.194

Dyslipidemia, kidney disease, and cardiovascular disease in diabetic patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2015.194

Lipid-lowering therapies, glucose control and incident diabetes: evidence, mechanisms and clinical implications.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2015.194

Balanced pan-PPAR activator bezafibrate in combination with statin: comprehensive lipids control and diabetes prevention?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2015.194

Statin therapy and new-onset diabetes: molecular mechanisms and clinical relevance

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2015.194

Statins are diabetogenic--myth or reality?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2015.194

Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S)

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2015.194

Statins for the primary prevention of cardiovascular disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2015.194

The effect of statins on the development of new-onset type 2 diabetes: a meta-analysis of randomized controlled trials

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2015.194

South-Asian population has a higher likelihood for diabetes risk for statins regardless of potency

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2015.194

Statin therapy and risk of diabetes in patients with heterozygous familial hypercholesterolemia or familial combined hyperlipidemia

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2015.194

Obesity in the new millennium

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2015.194

Insulin-secreting beta-cell dysfunction induced by human lipoproteins

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2015.194

Direct Effect of Cholesterol on Insulin Secretion: A Novel Mechanism for Pancreatic -Cell Dysfunction

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2015.194

Preferable effect of pravastatin compared to atorvastatin on beta cell function in Japanese early-state type 2 diabetes with hypercholesterolemia

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2015.194

What's preventing us from preventing type 2 diabetes?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2015.194

The discovery and development of HMG-CoA reductase inhibitors

31 March 2020

1 reference

12 December 2020

Mechanism of action and biological profile of HMG CoA reductase inhibitors. A new therapeutic alternative

1 reference

12 December 2020

Simvastatin effects on skeletal muscle: relation to decreased mitochondrial function and glucose intolerance.

1 reference

12 December 2020

Adipose tissue and cholesterol metabolism

1 reference

12 December 2020

Omental and subcutaneous adipose tissues of obese subjects release interleukin-6: depot difference and regulation by glucocorticoid

1 reference

12 December 2020

Regulation of cholesterol synthesis and storage in fat cells

1 reference

12 December 2020

Effects of simvastatin on glucose metabolism in mouse MIN6 cells

1 reference

12 December 2020

Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins

1 reference

12 December 2020

Localization of the insulin receptor in caveolae of adipocyte plasma membrane

1 reference

12 December 2020

Identifiers

DOI

10.1038/NRENDO.2015.194

1 reference

5 September 2017

1 reference